<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;div class="table-responsive"&gt;&lt;table class="table" border="0" cellspacing="0" summary="This table shows the date, time, and location of the meeting" cellpadding="2" sizcache="12" sizset="0" style="width: 643px"&gt;&lt;tbody sizcache="11" sizset="0"&gt;&lt;tr id="rrtr0"&gt;&lt;th id="a1" bgcolor="#cccccc" valign="top" align="left" style="width: 71px"&gt;Center&lt;/th&gt;&lt;th id="a2" bgcolor="#cccccc" valign="top" align="left" style="width: 158px"&gt;Date&lt;/th&gt;&lt;th id="a3" bgcolor="#cccccc" valign="top" align="left" style="width: 172px"&gt;Time&lt;/th&gt;&lt;th id="a4" bgcolor="#cccccc" valign="top" align="left" style="width: 238px"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr id="rrtr1"&gt;&lt;td id="rrtd0" height="61" valign="top" headers="a1" style="width: 71px"&gt;CDER&lt;/td&gt;&lt;td id="rrtd1" valign="top" headers="a2" style="width: 158px"&gt;April 14, 2015&lt;/td&gt;&lt;td id="rrtd2" valign="top" headers="a3" style="width: 172px"&gt;7:30 a.m. to 5:15 p.m.&lt;br /&gt;&amp;nbsp;&lt;/td&gt;&lt;td id="rrtd3" valign="top" headers="a4" style="width: 238px"&gt;FDA White Oak Campus&lt;br /&gt;10903 New Hampshire Avenue&lt;br /&gt;Building 31 Conference Center&lt;br /&gt;The Great Room (Rm. 1503)&lt;br /&gt;Silver Spring, Maryland&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;h3&gt;Agenda&lt;/h3&gt;&lt;p&gt;During the morning session, the committee will discuss the results of the cardiovascular outcomes trial (CVOT), Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus, for new drug application (NDA) 22350, Onglyza (saxagliptin) and NDA 200678, Kombiglyze XR (saxagliptin and metformin HCl extended-release) tablets manufactured/marketed by AstraZeneca AB.&lt;/p&gt;&lt;p&gt;During the afternoon session, the committee will discuss the results of the CVOT, Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care, for NDA 22271, Nesina (alogliptin); NDA 022426, Oseni (alogliptin and pioglitazone); and NDA 203414, Kazano (alogliptin and metformin) tablets marketed by Takeda Pharmaceutical U.S.A., Inc.&lt;/p&gt;&lt;p&gt;Saxagliptin and alogliptin are dipeptidyl peptidase-4 (DPP4) inhibitors, both indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Both CVOTs were submitted in accordance with the 2008 FDA Draft Guidance, &amp;ldquo;Diabetes Mellitus &amp;ndash; Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes,&amp;rdquo; to demonstrate that a new antidiabetic therapy to treat type 2 diabetes is not associated with an unacceptable increase in cardiovascular risk.&lt;/p&gt;&lt;h3&gt;Meeting Materials&lt;/h3&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt;&lt;h3&gt;Background Material&lt;/h3&gt;&lt;ul sizcache="1" sizset="43"&gt;&lt;li sizcache="1" sizset="43"&gt;&lt;a target="" href="[!--$wcmUrl('link','UCM426278')--]"&gt;2015 Meeting Materials, Endocrinologic and Metabolic Drugs Advisory Committee&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;h3&gt;Public Participation Information&lt;/h3&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Written submissions may be made to the contact person on or before March 31, 2015.&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between approximately 10:10 a.m. to 10:40 a.m., and 3:30 p.m. to 4 p.m. on April 14, 2015. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before March 23, 2015.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by March 24, 2015.&lt;/p&gt;&lt;h3&gt;Webcast Information&lt;/h3&gt;&lt;p sizcache="1" sizset="44"&gt;CDER plans to provide a free of charge, live webcast of the April 14, 2015 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. While CDER is working to make webcasts available to the public for all advisory committee meetings held at the White Oak campus, there are instances where the webcast transmission is not successful; staff will work to re-establish the transmission as soon as possible. Further information regarding the webcast, including the web address for the webcast, will be made available at least 2 days in advance of the meeting at the following website: &lt;a target="" href="[!--$wcmUrl('link','UCM426278')--]"&gt;2015 Meeting Materials, Endocrinologic and Metabolic Drugs Advisory Committee&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;CDER plans to post archived webcasts after the meeting, however, in cases where transmission was not successful, archived webcasts will not be available.&lt;/p&gt;&lt;h3&gt;Contact Information&lt;/h3&gt;&lt;ul sizcache="1" sizset="45"&gt;&lt;li sizcache="1" sizset="45"&gt;Philip Bautista, PharmD&lt;br /&gt;Center for Drug Evaluation and Research&lt;br /&gt;Food and Drug Administration&lt;br /&gt;10903 New Hampshire Avenue&lt;br /&gt;WO31-2417&lt;br /&gt;Silver Spring, MD 20993-0002&lt;br /&gt;Phone: 301-796-9001&lt;br /&gt;Fax: 301-847-8533&lt;br /&gt;E-mail: &lt;a href="mailto:EMDAC@fda.hhs.gov"&gt;EMDAC@fda.hhs.gov&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;ul sizcache="5" sizset="30"&gt;&lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;1-800-741-8138&lt;br /&gt;(301-443-0572 in the Washington DC area)- follow the prompts to the desired center or product area&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency&amp;rsquo;s Web site and call the FDA Advisory Committee Information Line to learn about possible modifications before coming to the meeting.&lt;/p&gt;&lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Philip Bautista at (301) 796-9001 at least 7 days in advance of the meeting.&lt;/p&gt;&lt;p&gt;Answers to commonly asked questions including information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: &lt;a target="" href="[!--$wcmUrl('link','UCM408555')--]"&gt;Common Questions and Answers about FDA Advisory Committee Meetings&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at &lt;a target="" href="[!--$wcmUrl('link','UCM111462')--]"&gt;Public Conduct During FDA Advisory Committee Meetings&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
